The press regularly reports on the results of IQWiG's work or asks the Institute’s researchers to comment on current developments and issues. A selection of recent articles is presented below:
After several scandals involving medical devices, a new EU regulation came into force in 2021. In the magazine "Gute Pillen - schlechte Pillen" (Good Pills - Bad Pills), Stefan Sauerland, Head of IQWiG's Department of Non-Drug Interventions, explains the benefits of the regulation for patients.
In a commentary for “Observer Gesundheit”, IQWiG Director Jürgen Windeler discusses the pros and cons of randomised trials. His conclusion: Randomisation cannot be beaten.
Jürgen Windeler spoke to “Deutschlandfunk Kultur” about questions concerning which services statutory health insurance must, are supposed to, and are allowed to pay for - and who decides on this for patients and on what basis.
Die ZEIT cites Stefan Lange, IQWiG‘s Deputy Director “In view of the increasingly expensive treatments for rare diseases, the question arises as to how long the health care system will be able to bear the enormous costs.“
Thomas Kaiser, Head of IQWiG's Drug Assessment Department, emphasizes that the European benefit assessment of drugs will not herald the end of AMNOG, the German assessment procedure.
In an interview with RiffReporter, Klaus Koch, Head of IQWiG's Health Information Department, explains how health information considers patients' needs. (RiffReporter.de)
